CORAL SPRINGS, FL–(Marketwire – September 30, 2010) –  Valiant Health Care, Inc. (OTCBB: VHCI) (PINKSHEETS: VHCI) announces that it has executed a term sheet with Atlantic Medical Supply, Inc., a Florida corporation (“AMS”), under which it will acquire all of the outstanding shares of AMS in exchange for cash, shares of Valiant’s common stock and options to purchase shares of Valiant’s common stock. 

Atlantic is a Joint Commission Accredited, Medicare Certified firm serving South Florida’s home medical equipment and supply needs since 1993. As one of the area’s largest retail suppliers of home health products and services, they provide superior customer service and top quality, state-of-the-art medical equipment and supplies.

The parties intend to quickly negotiate the stock purchase agreement and hope to close the transaction as quickly as possible, but no later than six months from the signing of the term sheet. Specific terms of the purchase will be provided when the stock purchase agreement is completed and filed with the SEC as required.

Ms. Salem, Co-founder of Accessible stated that “Acquisition of Atlantic a DME provider is the next important step toward achieving our objective of being a “One Stop Provider” of home health care” she continued “We are looking forward to having the Founders of Atlantic join our team, they bring 17 years each of successful experience in the home health care industry.”

About Valiant Health Care, Inc.
Through our Accessible Home Health Care division, we offer and sell a proven one of its kind franchise opportunity to establish and operate a full service medical and personal care Accessible Home Health Care franchise, under our distinctive brand and system. As of the date of this press release, there are 96 Accessible Home Health Care franchise units and one company-owned unit in 24 states, as well as in India and Kenya.

Accessible’s business model is designed to lead and direct the 21st Century demands of the long term home health care industry by offering a “Complete Home Healthcare Package™” and being a “One Stop Provider™.” Accessible’s primary mission is to provide the highest quality home health care services and products to its patients while adding value to the payers by reducing direct costs and the potential for fraud. Accessible’s next phase of growth includes an expansion of its company owned units by acquisition of Medicare certified home health care providers in strategic geographic markets.

Forward-Looking Statements
This release is not an offer to purchase or sell securities and may contain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Certain statements herein are or may be based on current estimates and projections about Valiant’s business, which are derived in part on assumptions of its management, and are not guarantees of future performance, as such performance is difficult to predict. Valiant assumes no obligation to update information concerning its expectations.

TAMPA, FL–(Marketwire – September 30, 2010) –  eFUEL EFN, Corp. (PINKSHEETS: EFLN) is pleased to announce that Riverside Assisted Living, Inc. (RAL) and eFUEL have executed a Letter of Intent and Understanding with regard to the following:

• It is the intention of eFUEL and RAL that within forty-five (45) days of the execution of the Letter of Intent and Understanding dated September 24, 2010, that they will enter into a Stock Exchange Agreement.

• The Principles of RAL agree to cause RAL to merge into eFUEL as a wholly owned subsidiary of eFUEL.

• The sole asset of RAL at the time of the aforementioned merger will be a 244,000 square ft. mortgaged hospital building on 16 acres located in Warren, Ohio.

About eFUEL EFN, Corp.:

eFUEL EFN, Corp. (“eFUEL”) is a publicly traded company listed on Pink Sheets under the symbol EFLN. eFUEL is an internet services company offering a wide variety of products including but not limited to background screening and verification sites, including www.ValiMate.com, www.VeritasID.com, and www.FastandEasyID.com, www.BackgroundAnswers.com and also www.VerifiAmerica.com, on-line dating sites www.outRAGEousEncounters.com and www.PositiveLove.com, and recently launched a new service called Easy ID, the fastest, easiest ID verification available on the internet. This product will be offered to all new members who purchase any www.eFUELstore.com service. Simply enter a person’s full name and birthday and the background information will be provided. This service is also available at the company’s main site www.eFUELstore.com or www.ValiMate.com. For additional Product information, go to our corporate site at www.eFUELcorp.com

Safe Harbor Statement: Certain Statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are subject to risks and uncertainties including, without limitation, changes in levels of competition, possible loss of customers, and the company’s ability to attract and retain key personnel.

BOCA RATON, FL–(Marketwire – September 30, 2010) –  XenaCare Holdings, Inc. (OTCBB: XCHO) announced today that it has signed a private label marketing agreement with Renaissance Publishing LLC covering three of its clinical supplement products.

Under the terms of the agreement XenaCare will supply Renaissance with finished product for private label marketing in the United States with packaging and branding provided by Renaissance.

Commenting on the agreement, Frank Rizzo, President and CEO of XenaCare, states, “We are very pleased to be working with Renaissance for U.S. private label marketing of these proprietary clinical supplement products. They fit into Renaissance’s growing portfolio of anti-aging dietary supplements that promote increased health, well-being, and life expectancy and allow us to concentrate our efforts and resources on Cobroxin™. We believe that the Renaissance strategy of providing education about its products along with its direct response sales model will result in greater awareness and sales of these unique products and look forward to a successful relationship with Renaissance.”

XenaCare expects to strengthen its distribution matrix for future product introductions through a strategic relationship with Renaissance. Renaissance currently has an established 150,000 customer base and is a multimillion dollar company.

For further information:

http://www.XenaCareHoldings.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our anticipated future sales results for our products are forward looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s expectations. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov.

IRVINE, CA–(Marketwire – September 30, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that it will be holding a special stockholder meeting on Thursday, Nov. 4, 2010 at the Irvine Hilton Hotel. At this meeting, stockholders will vote on the previously announced restructuring pursuant to which Sun is separating its operating assets and its real property assets by means of a distribution of SHG Services, Inc. stock. SHG Services, Inc. will own all of Sun’s operating assets and will be renamed Sun Healthcare Group, Inc. Stockholders will also be asked to vote on the merger of Sun with and into Sabra Health Care REIT, Inc., which will own substantially all of Sun’s real property assets, and intends to elect to be treated as a real estate investment trust effective Jan. 1, 2011. As previously announced, Sun expects that the restructuring will be completed in the fourth quarter of 2010.

The record date for stockholders entitled to vote at the meeting is Sept. 15, 2010. Sun expects that a proxy statement/prospectus describing the restructuring transactions will be mailed to stockholders on or about Oct. 4, 2010.

Richard K. Matros, Sun’s Chairman and Chief Executive Officer, commented, “We look forward to the opportunity to create increased shareholder value by separating into two publicly-held companies with independent growth strategies. This meeting is a significant step in the restructuring process.”

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25 states, of which 22,427 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary. 

Forward-Looking Statements

Statements made in this release that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,” “may” and similar expressions. Factors that could cause actual results to differ are identified in the public filings made by the Company with the Securities and Exchange Commission (SEC) and include the company’s ability to successfully complete the restructuring on terms and conditions satisfactory to Sun, as well as other risks and uncertainties, including those detailed from time to time in Sun’s SEC Commission filings. More information on factors that could affect the business and financial results are included in the company’s public filings made with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on Sun’s web site, www.sunh.com. The forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Sun’s control. Investors are cautioned that any forward-looking statements made by Sun are not guarantees of future performance. Sun disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.

Additional Information

In connection with the transactions described in this release, SHG Services, Inc. has filed with the SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc. has filed with the SEC a Registration Statement on Form S-4, each containing an identical prospectus and proxy statement for the special meeting. The definitive proxy statement/prospectus is being mailed to Sun stockholders on or about October 4, 2010. Before making any voting or investment decision, Sun stockholders and investors are urged to read the proxy statement/prospectus and other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed transactions. Stockholders will be able to obtain these documents free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders of Sun may obtain free copies of the documents filed with the SEC by contacting Sun’s investor relations department at (505) 468-2341 (TDD users, please call (505) 468-4458) or by sending a written request to Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E., Albuquerque, N.M. 87109. Investors and stockholders may also obtain a copy of these documents by requesting them in writing from Sun’s proxy solicitation agent, Innisfree M&A, at 501 Madison Avenue, New York, NY 10022, or by telephone at (212) 750-5833. 

Sun and its directors and executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Sun in connection with the transactions described in this release. Information about the directors and executive officers of Sun and their ownership of shares of Sun common stock are set forth in the Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on March 5, 2010 and in the definitive proxy statement relating to Sun’s 2010 Annual Meeting of Stockholders filed with the SEC on April 30, 2010. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants is also included in the definitive proxy statement/prospectus regarding the proposed transactions that is being mailed to Sun stockholders on or about October 4, 2010.

METHUEN, MA–(Marketwire – September 30, 2010) –  Suntron Corporation, a leader in the area of integrated Electronics Manufacturing Solutions (EMS) and Commercial Off-The Shelf (COTS) technology, with facilities across the US and in Mexico, will cut the ribbon at its new manufacturing site in Methuen, MA at 1:00 PM, October 05, 2010.

This new facility is the culmination of months of effort to combine the work previously done in two separate sites, into a larger, newer, state of the art facility. “The move to combine our northeast services under one roof clearly demonstrates Suntron’s commitment to the region and to our customers,” Roger White, VP and General Manager of the Eastern Region, stated. “We have expanded our box build manufacturing footprint and with significant capital investment, we are expanding our circuit card capacity and capabilities. I look forward to introducing everyone to the exciting new facility.”

Mike Churchill, VP of Operations for Suntron, commented on the teamwork needed to put this together. “We had amazing cooperation from so many local people and organizations, including our team of realtors from Colliers Meredith and Grew, the City of Methuen, the local Merrimack Chamber of Commerce, and the Massachusetts Business Development and Business Services groups. Their total support and guidance allowed us to accomplish our objectives in a very timely manner and we look forward to introducing everyone to our exciting new facility.”

The grand opening and ribbon cutting ceremony will be hosted by Ed Wheeler, President and CEO of Suntron. Lt. Governor Timothy P. Murray, Congresswoman Niki Tsongas, Mayor William M. Manzi, III and Joe Bevilacqua, President and CEO of the Merrimack Chamber of Commerce will all participate at the event. Factory tours will begin immediately following the ceremony.

For further information on this event and the day’s agenda, please visit http://www.suntroncorp.com.

About Suntron Corporation:
Suntron delivers complete manufacturing services and solutions to support the entire life cycle of complex products in the medical, aerospace & defense, Industrial, Networking & telecommunications, and semiconductor capital equipment market segments. Headquartered in Phoenix, Suntron operates four full-service manufacturing facilities and two quick-turn facilities in North America. Suntron’s services include engineering services, printed circuit card assembly, box build, large scale and complex system integration, COTS and test.

PERTH, AUSTRALIA–(Marketwire – September 29, 2010) –  After three years of collaborative research involving patients from The Busselton Health Study, drug discovery company Proteomics International announced the identification and analytical validation of 13 protein biomarkers for a significant complication of diabetes — diabetic nephropathy (kidney disease). In a presentation at the Human Proteome Organisation’s World Congress in Sydney, Australia, Dr. Richard Lipscombe, Managing Director of Proteomics International, revealed the findings that could benefit many of the 250 million people worldwide who have diabetes.

“Applying our uniquely accredited proteomics biomarker expertise to patient samples (plasma) from the Busselton Health Study and the Fremantle Diabetes Study allowed us to analyze three well characterized clinical cohorts of selected disease groups (adults who had Type II diabetes and diabetic nephropathy),” said Dr. Lipscombe. “The protein biomarkers that we found could now allow for the prediction of those patients who would progress to the development of kidney disease and provide new targets for drug therapies that prevent the onset of this serious complication.“

Proteomics International is actively seeking partners to further qualify and commercialize its patented diabetes biomarker portfolio.

The protein biomarker discovery and validation approach included the analysis of pooled plasma samples for differential protein expression, i.e. proteins that are found at different levels in the diabetic disease state relative to the normal diabetic state. Candidate biomarkers were identified from iTRAQ labelled samples by 2D-LC MALDI TOF/TOF mass spectrometry, an emerging technique in proteomics. This discovery phase identified 130-200 proteins per cohort and across all studies over 50 proteins showed significant differences in concentrations. Biomarker candidates were validated in a second approach using the advanced mass spectrometry technique Selected or Multiple Reaction Monitoring (SRM/MRM) to carry out concentration analysis on individual patient plasma samples. Statistical data analysis of the validation phase identified 13 putative protein biomarkers for diabetic nephropathy across the studies, including proteins involved in metabolism, inflammation and oxidative stress. The complexity of the diabetic kidney disease suggests that there would not necessarily be one biomarker but a set of biomarkers (signature) in varying degrees to characterize the diabetic nephropathy state. These biomarkers can be used as diagnostic tools or new drug targets.

About Proteomics International Pty Ltd
Proteomics International is both a drug discovery company and contract research service provider. Proteomics International combines the most advanced high throughput mass spectrometry instrumentation (MALDI TOF-TOF and LC-MS/MS) and a team of qualified scientists with proven expertise in protein and peptide chemistry. Proteomics International is the only company globally to achieve laboratory accreditation to International Standard ISO/IEC 17025:2005 for provision of proteomics services. The accreditation is a widely used benchmark for US Federal testing facilities and strengthens the company’s licensing position to deliver drug development data that is of the highest scientific integrity. The company has two focal research activities: new peptide drugs from venoms, and the discovery and use of biomarkers; both analyses build upon its proprietary transformative Bioven process.

HOUSTON, TX–(Marketwire – September 29, 2010) –  DHEA (Dehydroepiandrosterone) is the most abundant base building block for hormones in our bodies. We gradually make more and more DHEA until about age 25; then produce less and less as time passes. By age 35, the right DHEA supplement can provide noticeable advantages to help us look and feel our best and diminish many aspects of aging. But it must be used correctly.

Medical research shows DHEA must be delivered to the body as a transdermal cream rather than as a pill supplement.

Oral DHEA taken as a pill is destroyed by the “first-pass effect” of the liver. The liver filters out most DHEA before it can do any good; what does get into the bloodstream is DHEA-S (DHEA sulphate).

DHEA-S is a different pro-hormone and has different benefits than DHEA. Medical research shows DHEA is converted into DHEA-S, but not the other way around. DHEA-S is not converted by the body into DHEA. (Hammer et al)

Twist 25 supplements DHEA rather than DHEA-S.

Most research studies of “DHEA” were done using oral DHEA. As a consequence these studies showed little significant benefit to “DHEA”(sulphate) supplementation. No wonder: These studies did not test DHEA with the proper method of administration.

DHEA must be delivered to the body properly as a transdermal DHEA cream – Twist 25.

Medical research shows the human body metabolizes most DHEA into other hormones in the skin (the dermis). The skin is where we use most of the DHEA we make. So Twist 25 cream actually provides exactly what the body produces naturally (bioidentical DHEA) where we use it (in the skin). (Labrie et al)

This is the other key reason DHEA should be provided to the body as a transdermal DHEA cream – Twist 25.

Twist 25 DHEA supplement cream is the highest quality most effective anti-aging health product available. Twist 25 is tested for safety and efficacy.

About Health2Go, Inc.
Health2Go, Inc. develops, manufactures and provides leading-edge top quality anti-aging products. To learn more about Health2Go, Inc. or their anti-aging and wellness products, please visit www.twist25.com or http://store.twist25.com

Fabian Hammer, Sandra Subtil, Philipp Lux, Christiane Maser-Gluth, Paul M. Stewart, Bruno Allolio and Wiebke Arlt. No Evidence for Hepatic Conversion of Dehydroepiandrosterone (DHEA) Sulphate to DHEA: In Vivo and in Vitro Studies. Journal of Clinical Endochrinology and Metabolism Vol. 90, No. 6 3600-3605

Fernand Labrie, Alain Belanger, Rene Berube, et al. University of Toronto Medical School. The Journal of Steroid Biochemistry and Molecular Biology Vol 103, Issue 2, February 2007, Pgs 178-188

Click here to see all recent news from this company

MUNDELEIN, IL–(Marketwire – September 29, 2010) –  Despite traditional differences among the chief constituents of long-term care, the new survey process can be a “win-win” for everyone, which will drive significant quality improvements in our nation’s nursing homes, said Kansas Governor Mark Parkinson and the incoming president of the American Health Care Association and National Center for Assisted Living (AHCA/NCAL), the nation’s largest long-term care association. Governor Parkinson made these comments while speaking at Medline Industries, Inc.’s second annual Long-Term Care Quality Summit, in New York City. More than 150 leaders from the nation’s long-term care community are attending the two-day forum focused on how nursing homes can meet the changing expectations for quality among their residents and families.

“Historically there has been mistrust among providers, regulators and advocacy groups over the traditional survey process and what its goals are,” said Governor Parkinson. “But I am optimistic now because we all want quality care in our nursing homes, and the new Quality Indicator Survey (QIS) process can help make this happen.”

Governor Parkinson said the QIS is more objective than the traditional survey process and focuses on important quality criteria, including a robust care plan, promoting a safe environment and keeping residents active. He emphasized that for resident quality to improve, it was crucial that these criteria be measured and homes be held accountable to maintaining high standards.

In addition to Governor Parkinson, topics being discussed at the Summit include the changing regulatory expectations for the long-term care industry and how nursing homes can implement a system to continuously improve quality of care and life for their residents.

Other speakers include: Anthony Rodgers, new CMS Deputy Administrator for the Center for Strategic Planning; Robert F. Kennedy, Jr.; Andy Kramer, MD, chief executive officer of Nursing Home Quality and professor of medicine, University of Colorado; Neil Pruitt, Jr., chairman and CEO, UHS Pruitt Corporation; Jim Foy, president and CEO, St. John’s Riverside Healthcare System, Yonkers, NY; Barbara Baylis, senior vice president of clinical operations, Kindred Healthcare, Inc.; Mary Ousley, president of Ousley & Associates; Elizabeth Ayello, president of Ayello, Harris and Associates; and Kevin Yankowsky, partner in the health law litigation group of Fulbright & Jaworski L.L.P.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

TAMPA, FL–(Marketwire – September 29, 2010) –  Sage North America today announced that the Sage Healthcare Division, a major provider of electronic health records (EHR) and practice management software serving approximately 80,000 physicians throughout the United States, has been named a preferred vendor by the Ohio Health Information Partnership to make available the Sage Intergy Meaningful Use Edition to all of the Regional Extension Center’s (REC) thousands of participating healthcare providers.

The Ohio Health Information Partnership (OHIP) is a nonprofit, funded through a combination of state funds and federal grants, whose mission is to advance the adoption, implementation and meaningful use of health IT among health care providers to improve the safety, quality, accessibility, availability and efficiency of healthcare for the citizens of Ohio. The organization was created by the American Recovery and Reinvestment Act (ARRA).

Fred Richards, CIO and COO of OHIP, said, “We look forward to working with Sage Healthcare to help us achieve our mission to improve the quality and value of health in Ohio by increasing the use of EHRs.”

The Ohio partnership will provide services that will offer practices EHR implementation assistance making the selection of an EHR system easier for healthcare providers, as well as helping providers meet meaningful use standards. Meeting these standards is necessary for physicians to qualify for financial incentives through Medicare and Medicaid.

The overall goal of OHIP is to improve healthcare quality, outcomes and experience for the citizens of Ohio. OHIP is committed to assisting more than 6,000 physicians adopt and meaningfully use an EHR by 2012.

As a Preferred Vendor for OHIP, Sage will be offering its electronic health record products and services to OHIP provider members. “The Sage mission echoes that of the Ohio Information Partnership in that our ultimate goal is to improve healthcare outcomes throughout the United States through the implementation of affordable and effective health information technology,” said Ken Ernsting, Vice President of Business Development for Sage Healthcare. “Because of this mission, Sage is dedicated to serving regional extension centers and the provider community here in Ohio and beyond.”

The Sage Intergy Meaningful Use Edition is a comprehensive clinical, financial and administrative health information technology solution that assists physicians in continuing to advance the quality and efficiency of care they deliver. The Sage Intergy family of products includes integrated practice management, electronic health records, clinical and business intelligence and tools for online patient engagement. Providers can access Sage Intergy from multiple practice locations, from home, or other remote locations either through a central patient database server, or as a Sage-hosted solution on a monthly subscription basis.

Sage Intergy easily tracks the details of a patient’s clinical history, shares and manages clinical information and combines complex medical practice functions into easy-to-navigate menus. Sage Intergy features centralized financial operations including billing, reporting, task management, and fully integrates with EDI services, Sage Intergy Practice Portal, Sage Intergy RIS and Sage Practice Analytics.

Clinics eligible to utilize Ohio Health Information Partnership’s subsidized services include Priority Primary Care Providers (PPCP) in the area of family medicine, obstetrics, and gynecology, general internal or pediatric medicine. In addition, practices must be either individual or a small group practices (defined as 10 or fewer professionals with prescriptive privileges in the practice) primarily focused on primary care; public and critical access hospitals; and community health centers and rural health clinics.

About Ohio Health Information Partnership
Ohio Health Information Partnership mission is to advance the adoption, implementation and meaningful use of health IT among healthcare providers and facilitate and develop an electronic health information exchange (HIE) to improve the safety, quality, accessibility, availability and efficiency of healthcare for the citizens of Ohio while creating a secure, sustainable health information exchange that ensures the protection of all patient records, enables providers to access necessary, patient-authorized health information and improves the overall level of health care provided throughout the state of Ohio.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers, including medical practices in the United States. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the Web site at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

BETHESDA, MD–(Marketwire – September 29, 2010) –  GetWellNetwork, Inc. today announced that Sharp Memorial Hospital, a Magnet hospital and part of Sharp HealthCare, a Malcolm Baldrige National Quality Award recipient, has selected the Company’s award-winning interactive patient care solution to enhance the patient care experience and streamline clinical workflows. Sharp Memorial Hospital in San Diego, California will use the GetWellNetwork^® solution to provide superior patient education, high-tech amenities and enhanced communication with their caregivers.

“When we evaluated our goals against solutions on the market, it became very clear that GetWellNetwork was our best option,” said Susan Stone, chief nursing officer, Sharp Memorial Hospital. “GetWellNetwork clients have documented impressive improvements in clinical outcomes, patient safety and patient satisfaction. In addition, the company offered something other solutions lacked — proven integration with our EMR system for efficient automation of nursing workflows and the ability to extend The Sharp Experience when patients go home.”

The GetWellNetwork system will provide Sharp Memorial Hospital with a systematic and consistent approach to patient education and communication with caregivers and hospital staff. By integrating with the hospital’s Cerner^® EMR system, patients will access personalized medical information as soon as they arrive in their rooms and will be encouraged to learn about their diagnosis, treatment plan and any upcoming medical procedures through the GetWellNetwork system.

In addition, clinicians will be able to track patients’ progress and comprehension of their treatment plans and prescribed education materials, which will be documented automatically into patients’ records through the bi-directional integration with the Cerner EMR. The result is a consistent process for documentation of patient records, which in turn offloads non-clinical tasks from clinicians. 

The GetWellNetwork solution will also provide a wide range of entertainment features to help patients relax and stay connected with their tech-savvy friends and families. Patients can watch a variety of Hollywood movies, play video games, listen to music on Pandora, and surf the Internet, as well as stay connected via email and social media sites.

“Sharp has earned a national reputation for delivering exceptional patient care, and we had a unique opportunity to work intimately with their leadership team as they evaluated potential partners for the new hospital,” said Michael O’Neil, CEO and founder of GetWellNetwork, Inc. “We are very proud to be selected as the interactive patient care solution of choice by Sharp, and we look forward to collaborating as we implement a digital platform that will impact patient outcomes throughout the patient journey.”

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

About Sharp Memorial Hospital
With a tradition of excellence since 1955, Sharp Memorial Hospital is recognized internationally for outstanding programs in emergency and trauma services, surgery, cardiac and vascular care, cancer treatment, rehabilitation, orthopedic and neurological services, women’s health, weight loss surgery, multi-organ transplantation and home care.

A Magnet-designated facility for nursing excellence, Sharp Memorial completed an expansion in January 2009 to become San Diego’s first hospital with all private patient rooms. The new 315,000-square-foot, 334-bed structure, named the Stephen Birch Healthcare Center, is also the first hospital in San Diego to open since 1993. 

Sharp Memorial is part of Sharp HealthCare, the region’s largest health care provider and a 2007 Malcolm Baldrige National Quality Award recipient. To learn more about Sharp Memorial, visit www.sharp.com/memorial or call 1-800-82-SHARP (1-800-827-4277).

Click here to see all recent news from this company

CAMPBELL, CA–(Marketwire – September 29, 2010) –  Saama Technologies, Inc., a pure-play business intelligence (BI) solution provider, and MeLLmo, Inc., provider of innovative mobile BI apps including Roambi, today announced a system integrator partnership that will allow mobile workers from the world’s leading organizations to more easily — and usefully — access data residing in business intelligence solutions from their iPhones, iPads and other mobile devices, providing for more agile decision making. Saama will demonstrate its new end-to-end mobile BI solution, Saama mBI™, at the ASUG BusinessObjects User Conference, on Oct 4-7 in Orlando, Florida, where it is an event sponsor.

According to Murali Pabbisetty, head of Saama’s mobile business intelligence practice group, mobile workers have the same information needs as office staff, but retrieving this critical information, in a format that is usable, has been a significant challenge for enterprise organizations, one that is made more complicated by the proliferation of devices of varying shapes, sizes and technical characteristics.

“Our offering, which includes proprietary automation software and an innovative data visualization methodology, partnered with the Roambi solution — which is well known to be the leading system for extending critical business reports and data out to mobile devices via dashboards — helps enterprises overcome these challenges and realize a level of proactive decision making previously unavailable,” said Pabbisetty. “Together, we can provide a combination of mobile business intelligence experience, skills and software that is unique in the industry and a tremendous asset to our customers.”

“Saama has implemented business intelligence solutions for many of the world’s largest organizations and will be an excellent system integrator partner, given the firm’s dedicated Mobile BI Practice,” said Santiago Becerra, MeLLmo co-founder and CEO. “There’s more to a mobile BI implementation than shrinking reports to fit a mobile device. Enterprises need to understand how the data is going to be used and how that is impacted by a device’s size, shape, orientation, speed, resolution and network. They also need to understand that they have new options, like Roambi, for visualizing their critical data in ways never before available. Having worked through the process many times before, MeLLmo and Saama have a unique appreciation for these issues, and we’ve mastered the art of helping organizations achieve maximum value from their mobile business intelligence implementations.”

Saama will demonstrate its new end-to-end BI solution, Saama mBI, from its booth — #208 — at the ASUG BusinessObjects User Conference October 4-7, 2010 in Orlando, Fl.

Saama is also leading three of the educational sessions within the co-located ASUG Fall Focus: Roadmap to ROI conference, along with customers Cisco Systems and Affiliated Computer Services (a Xerox Company). The three sessions, all held on Tuesday, October 5^th, are detailed below:

• Change Management for an Enterprise powered by SAP BusinessObjects
  • Time: 2:45 PM – 3:45 PM
  • Speakers: Timothy Beaver, Affiliated Computer Services (ACS), a Xerox Company, and Murali Pabbisetty, Saama Technologies
• Connecting Heterogeneous BI Silos: A Cisco Story
  • Time: 4:00 PM – 5:00 PM
  • Speakers: Tim Chandler and Milind Joshi, Cisco Systems, and Balaji Rajagopalan, Saama Technologies
• Ensuring a Timely and Efficient Implementation of SAP ESS/MSS
  • Time: 1:30 PM – 2:30 PM
  • Speaker: Bhushan Dadia, Saama Technologies 

About MeLLmo
Founded in 2008, MeLLmo is reinventing the mobile business application to improve the productivity and decision-making of on-the-go employees. The company’s flagship product, Roambi, is an iPhone/iPad application that makes business data and reports easy to access, navigate and interact with right from a handheld device. Headquartered in San Diego, CA, MeLLmo has a worldwide customer base of Fortune 500 companies and SMBs across a diverse range of industries including: telecommunications, biotechnology, pharmaceuticals, consumer technology, packaged goods, and others. For more information about MeLLmo visit http://www.mellmo.com.

About Saama Technologies
 Saama Technologies, Inc. is a pure-play business intelligence solution provider which continues to revolutionize the way organizations make decisions through business intelligence. Since 1997, the company has combined its extreme BI technology expertise, unique intellectual property portfolio and strong relationships with the industry’s leading technology providers to deliver pure business intelligence to the world’s largest information-focused organizations. Saama’s customers are Fortune 500 organizations within a wide range of industries, including life sciences, technology, financial services, and the public sector. Saama recently acquired data-integration software and NIEM-conformance pioneer Sypherlink, which operates as an independent, wholly-owned subsidiary. For more information, visit www.saama.com.

Saama Technologies and Pure Business Intelligence are trademarks of Saama Technologies, Inc. The names of other actual companies, organizations and/or products/services mentioned herein may be the trademarks of their respective owners.

ALISO VIEJO, CA–(Marketwire – September 29, 2010) – Enclarity Inc., a leading healthcare information solutions company, today announced its October 2010 tradeshow schedule. The company will exhibit and attend three shows to educate payers about the importance of maintaining accurate provider records.

“These industry tradeshows allow us to share our expertise in cleansing provider databases,” said Scott Marber, senior vice president, sales and marketing, Enclarity. “We use the outings to raise awareness and offer cost-effective solutions to the problems created by inaccurate provider data. Increasing the accuracy of your provider data can save a payer hundreds of thousands, if not millions, of dollars per year.”

Oct. 5-8, 2010 Blue Cross Blue Shield Association Blue National Summit
Enclarity will exhibit in booth #316. The show will be attended by Marber as well as Enclarity team members Jasson Griswold, sales director, and Stephanie Rose-Belcher, vice president, payer solutions.

Oct. 13-14, 2010 National Association of Health Data Organizations 25th Annual Conference
Enclarity will exhibit in booth #4. The show will be attended by Enclarity team members Tom Nicholson, sales director, and Sioban McCoy, senior account manager.

Oct. 18-20, 2010 California Association of Health Plans 25th Annual Conference
Enclarity will exhibit in booth #510. The show will be attended by Marber and Griswold.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

ASHEVILLE, NC–(Marketwire – September 29, 2010) –  Jaan Ferree, an interior designer based in Asheville, NC specializes in designing public spaces for healthcare, colleges, churches and retreats. Asheville City Council appointed Ferree to the Public Art Board. Her interior design ideas include work by Western North Carolina (WNC) artists and craftsmen.

North Carolina Arts for Health invited Ferree to speak at the Spirit of Place, Places of Spirit conference on October 16, 2010, co-sponsored by Mountain Area Health Education Center (MAHEC). She will present an overview of her intentional process of creating healing environments for health care professionals, patients and families. In these sacred spaces, the public can meditate, nurture their spirits, and connect with the divine in a soothing environment. Participants will tour Mission Hospital chapels. 

Ferree recently completed the interior design of Saint Joseph’s Chapel, a three-year process bringing an interfaith focus to Mission Hospital chapels. To the right of the entrance, the Chapel of Mercy resembles a mini church design, with chairs, kneelers, pew and Stations of the Cross. A glass case across from this room holds symbols of various religions: Buddha, Shiva/Shakti, sage bundles and a feather, a Quran, prayer rug, and Islamic prayer beads and a Menorah. The chapel incorporates signatures of Ferree’s work — a labyrinth walk, journaling table, original stained glass pieces hanging from the skylight, an enlarged photograph of an apple tree in bloom, and a murmuring fountain to complete the overall feeling of calm and serenity. 

“What drew us to Jaan was her inclusion of local artistry and nature in her design aesthetic, her experience in designing labyrinths, and her dedication to creating a space which invites all to enter and encounter the holy,” commented Jerene Broadway, Staff Chaplain for Mission Hospital. “We were delighted to discover that her design and leadership embodied our vision to weave diverse religious traditions into a single tapestry,” she added.

Ferree has designed indoor and outdoor labyrinths, meditation gardens and sacred interior spaces for churches and retreat centers, including Valle Crucis Conference Center, Davidson College and Carpe Diem Farms. She will design an outdoor pavilion for use as a meditation and yoga center at Horse Sense of the Carolinas, where equine therapy is practiced.

To view samples of Jaan Ferree’s interior designs, or for a consultation, visit Intentional Designer, email [email protected] or call 828-252-8718. 

DURHAM, NC–(Marketwire – September 29, 2010) – Mi-Co announced today the release of a new white paper providing a snapshot of what different enterprise users look for in mobile data collection devices and software systems. The white paper serves as a follow-up analysis of a survey recently conducted by Mi-Co, on the same topic. The paper also provides a brief overview of the state of Enterprise Mobility today including findings that would be of interest to software companies, enterprises with mobility interests, governmental organizations and more.

Read what’s popular in electronic data collection for organizations based on Mi-Co’s survey results of 8,500 professionals. Understand the nuances and characteristics end-users favor in data input platforms. For example, the survey showed that touch-filled forms are highly preferred (61.5%) versus electronic forms populated through a keyboard (51.9%) or stylus (48.1%), yet the use of a Tablet PC on a Windows OS trumps all other types of mobile devices such as the iPad and Blackberry on preference ratings. 

Elodia Cole, Mi-Co customer at Medical University of South Carolina says, “The ability to quickly assess data quality and monitor study processes is a prime motivation for our interest in moving towards enterprise mobility for conductance of clinical trials data collection. Our ultimate goal is to minimize data queries, an often time consuming and under budgeted aspect of clinical trial activities. We are currently assessing various technologies that better integrate the data collection and data management processes so that study monitors can review data as it is being collected and intervene as necessary.“

Learn more about how applying electronic mobility to your data collection processes can streamline and positively impact workflows in your enterprise. Visit us at: www.mi-corporation.com or to request a copy of the white paper or email us at [email protected]. 

About Mi-Co
Mi-Co, a leading provider of mobile data collection solutions, provides software to automate paper forms-based business processes. Mi-Co’s enterprise Mi-Forms Software System provides flexible electronic forms design for data capture using digital ink and has proven capabilities for the communication of forms-based data. Mi-Forms support Tablet PCs, Digital Pens, iPads, Pocket PCs, signature capture devices and industry standard software technologies. Mi-Co reaches historically paperwork intensive markets such as healthcare and government and supports an extensive network of channel partners. For more information on Mi-Co, visit www.mi-corporation.com

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – September 29, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (www.mmrglobal.com) announced today it has filed a patent application for an open integration tool by which patient data from any practice management system can be seamlessly uploaded into the Company’s MMRPro system (www.mmrprovideos.com) or other electronic records systems. Called the Practice Management System Integration Application (PMSIA), the tool is being designed for administrators in physician offices, hospitals and alternative care sites to facilitate the efficient population of patient information from a healthcare provider’s practice management system into the MMRPro Web-based application. Once patient data is transferred to MMRPro, that patient’s records can be scanned and deposited into an MMRPro virtual patient chart where it can be retrieved over any Internet-connected computer on demand.

The Company believes that one of the biggest challenges physician offices face is moving patient data from their practice management system to an electronic medical records (EMR) system effortlessly. The new integration tool is designed to make it easier for any healthcare professional to convert their office to a new EMR-type system quickly and securely.

Robert H. Lorsch, Chairman and CEO of MMRGlobal, said, “This universal tool represents a way that can help accelerate the growth of health information technology while allowing a faster, more efficient integration of MMRPro into any healthcare professional’s office.”

MMRGlobal’s integration tool will work with any file format, including .csv, .txt, flat file or HL7, and extract data from any open data connectivity (ODBC) compliant data source.

“The flexibility offered by the integration tool also makes it a universal solution for transferring data from practice management systems to most electronic medical records systems, opening the door for MMRGlobal to position its products as a patient portal to competitive EHR systems and potentially creating opportunities for incremental licensing revenue,” Lorsch added.

The applet is expected to be delivered with MMRPro implementations during the fourth quarter. For additional information about the Company and its products and services, visit www.mmrglobal.com and follow Bob Lorsch’s blog at http://blog.mymedicalrecordsinc.com/.

About MMRGlobal, Inc.

MMR Global, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the health care community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product and feature introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the health care industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Click here to see all recent news from this company

SAN CLEMENTE, CA–(Marketwire – September 29, 2010) –  Micro Identification Technologies, Inc. (OTCBB: MMTC) (MIT) announces that it has entered into a Securities Purchase Agreement in the form of an 8% convertible note with a New York-based privately held investment banking firm. The Note matures on May 18, 2011 and is convertible into common shares. The firm may convert any or the entire unpaid principal note prior to the maturity date, commencing 180 days following the date of the Note.

This funding is in addition to our recent announcement of the equity financing commitment from Dutchess Capital. MIT expects to receive additional funding from this or other firms under similar conditions in the upcoming months to accelerate its planned production launch and marketing campaign later this year. MIT’s Chairman and CEO, Michael Brennan, stated, “This funding will significantly help MIT achieve its near term goals and, together with expected future funding, will enable MIT to exceed its short and medium term plans.”

MIT will be hosting a Webinar at 1:00 PM PDT today to provide an update of its current business and future plans. Attendees may register for this Event at: https://www3.gotomeeting.com/register/427693966

About Micro Identification Technologies:

MIT is a California-based public company that has developed and patented a rapid microbial identification (ID) System that revolutionizes the pathogenic bacteria ID process and can annually save thousands of lives and tens of millions of dollars. The System IDs bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process is totally GREEN requiring only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually — with food safety accounting for over $3 billion — having expanded at a rate of 9.2 percent annually since 1998. Current growth projections are at 30 percent annually with test demands driven by major health, safety and homeland security issues. www.micro-identification.com

MIT has demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT has performed over 300 tests for the identification of the aforementioned contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and is easily expandable. The identification process has been verified by North American Science Associates, Inc. (NAMSA), an independent, internationally recognized biological testing laboratory. The NAMSA Test Report is available from the Company and, in MIT’s opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.

EDEN PRAIRIE, MN–(Marketwire – September 29, 2010) –  Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that it has engaged two leading industrial design and software firms to develop the next generation electronic power and software driver for its C-Pulse^® Heart Assist System. By miniaturizing the separately-housed controller and driver and combining them into one compact unit, Sunshine Heart is broadening future clinical and commercialization opportunities for C-Pulse.

The Company has entered joint development programs to develop a smaller, quieter and lighter single-control system for use in the U.S. pivotal clinical trial, which is expected to commence once the FDA approved IDE feasibility study is completed. The new C-Pulse design will integrate the power driver and battery pack into one unit, significantly reducing the size and the weight of external components. These external design changes will greatly improve mobility and comfort for the patient without altering C-Pulse implantable components or the way in which the device functions inside the body. The new single unit will also feature a number of software enhancements that are intended to allow medical professionals to collect additional data to improve patient management.

Sunshine Heart Chief Executive Officer Dave Rosa said, “Due to its small internal components, the C-Pulse can ideally be implanted through minimally invasive procedures as opposed to a full sternotomy procedure. Now, with the redesign of C-Pulse external components, the system will be more ergonomically appealing and comfortable for patients. Our ultimate goal is to make the C-Pulse a fully-implantable system which, much like a pacemaker, can be easily implanted and effortlessly managed by patients.”

Co-principal medical investigator for Sunshine Heart’s FDA approved IDE feasibility study, William T. Abraham, MD, Professor of Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University Heart Center in Columbus, Ohio, said, “Reducing the size and bulk of the external system combined with a less-invasive surgical procedure will dramatically expand the use of the C-Pulse among physicians. This treatment has the potential to transform the way in which heart failure is treated and I am eager to see this treatment reach more patients.”

The C-Pulse heart assist system is designed to treat patients suffering from the debilitating effects of moderate to severe heart failure caused by a failing left ventricle (the left heart chamber). The C-Pulse System features a unique balloon counterpulsation technology that is designed to assist the left ventricle by reducing the workload required to pump blood throughout the body. In addition, it increases blood flow to the coronary arteries. Combined, these potential benefits may help reverse the heart failure process or maintain the patient’s current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants.

The C-Pulse System is an earlier intervention than other mechanical therapies, such as LVADs. This device does not make direct contact with patient’s blood and it can be turned on or off at any time, allowing patients intervals of freedom to perform certain activities. The C-Pulse System can also be implanted as a minimally invasive procedure, thereby potentially reducing procedural time, hospital stays, overall cost and patient risk as compared to a traditional sternotomy.

About the C-Pulse^® Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously.

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sense lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and lead are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices, such as left ventricle assist devices (LVADs).

About Sunshine Heart^®

Sunshine Heart^® (ASX: SHC) a global medical device company committed to the commercialization of the C-Pulse^® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. C-Pulse^® relieves the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the U.S. Food and Drug Administration (FDA) to conduct a 20-patient U.S. clinical trial with the C-Pulse^® System and the study will reach seventy-five percent enrollment by September 30, 2010. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit www.sunshineheart.com.

Click here to see all recent news from this company

SACRAMENTO, CA–(Marketwire – September 28, 2010) –  A statewide effort in California is bringing hospitals, physician organizations, and other health care providers together to reduce 30 and 90-day readmission rates by 30 percent by December 31, 2013. Known as ARC — “Avoid Readmissions Through Collaboration” — the initiative helps hospitals adopt evidence-based models and interventions known to reduce readmissions.

“Avoidable hospital readmissions are a symptom of inefficiency and poor quality that result in millions of wasted health care dollars every year in California,” said Bruce Spurlock, MD, coordinator of the initiative and CEO of Convergence Health Consulting.

Ninety percent of Medicare readmissions within 30 days are unplanned and the total cost exceeds $17 billion annually, according to recent studies.

“Fortunately, we have evidence-based models and tools for lowering readmissions and improving transitional care. Hospitals and other providers are anxious to learn about and put these tools into place so that patients don’t suffer the risks associated with poorly planned transitions from the hospital back home or to other care settings,” said Spurlock.

Already, nearly 150 hospital, medical group, health plan and nursing home leaders from five San Francisco Bay Area counties have met and begun to discuss what will be required to more quickly lower readmission rates and to improve transitional care processes.

ARC will organize “Learning Communities” that include hospitals and other provider organizations (e.g., medical groups/IPAs, home health, long term care, health plans) that want in-depth education — conferences, peer-to-peer forums and webinars — that focuses on practical, evidence-based approaches to reducing readmissions. The ARC-sponsored educational events will include regional and national experts.

Within the Learning Communities will be Action Networks consisting of those hospitals and their outpatient partners that receive additional on site and remote support from improvement advisors. Advisors will support Action Network participants through examination of hospital readmission data, review of current discharge processes and facility specific training. Select Action Network participants are also eligible to apply for 2011 planning grants from the Gordon and Betty Moore Foundation.

“Hospitals face intense pressure to lower unplanned readmissions and to improve transitional care,” said Debby Rogers, RN, MS, VP Quality and Emergency Services, California Hospital Association. “We are excited about this new collaborative and the opportunity to work together to solve this common challenge.”

Medicare already reports hospitals’ readmission rates for heart attack, pneumonia and heart failure at http://www.hospitalcompare.hhs.gov. But beginning in 2013, hospitals will be penalized one percent of their Medicare reimbursement if readmission rates exceed expected levels. The penalty increases in subsequent years.

“We are seeing tremendous interest from physician groups in working more seamlessly with their hospital partners. The ARC collaborative will provide a structure to accelerate this effort,” said Diane Stewart, Director, Performance Improvement, Pacific Business Group on Health. 

Successfully reducing unplanned readmissions and improving care transitions involves several guiding principles that ARC will emphasize: maintaining a patient-centered focus; “getting into the weeds” to better understand the complex discharge planning and transitional process; customizing existing transitional care models to fit a hospital’s own culture and systems; and reinforcing effective practices by hospital staff.

Other critical components for effective care transitions include improving patients’ capabilities for self-management and medication adherence, as well as encouraging adoption of transitional care technologies.

The three year, one million dollar initiative is funded by the Gordon and Betty Moore Foundation (www.moore.org), with additional support for the project launch from The California Health Care Foundation (www.chcf.org).

Click here to see all recent news from this company

JUPITER, FL–(Marketwire – September 28, 2010) –  Shopping for insurance is all about finding the right coverage at the right price, but studies show a majority of people don’t know what to look for. 877-FOR INSURANCE takes the guesswork out of selecting the right insurance company, offering policies to fit the needs of any consumer.

Whether it’s home, life, auto or health, 877-FOR-INSURANCE’s experienced agents are trained to help consumers every step of the way. Selecting the right coverage plan is only the beginning. 877-FOR-INSURANCE’s agents research potential discounts, working with more than 30 companies to provide consumers with the best rate possible.

“Insurance is necessary to protect not just your belongings, but your loved ones as well,” says Jason Brian, President and CEO of 877-FOR-INSURANCE. “It’s important that you know the basics, so you can make an informed decision with full context. 877-FOR-INSURANCE’s agents know the ins and outs of every type of policy, so they’re able to pass that information along to the consumer.”

877-FOR-INSURANCE understands that in today’s world, consumers have a variety of insurance options available to them. Convenience is key, but so is finding the right coverage. 877-FOR-INSURANCE’s agents look at income, assets, responsibilities and plans for the future — to give consumers confidence that they’re not just covered, but really protected.

“So many people are overpaying for their policy, and they’re not even getting the coverage that they need,” adds Brian. “By truly partnering with our clients, and learning more about them, we’re able to provide them with coverage at the most reasonable rate.”

About 877-FOR-INSURANCE
877-FOR-INSURANCE is a full service insurance provider, offering health, life, auto and home insurance policies. They aim to surpass customer expectations, providing plans that are well-priced and of the highest quality. For more information call 877-FOR-INSURANCE or go to www.877forinsurance.com.

About BDD Marketing and Management
BDD Marketing and Management is a full service company. Founded on a deep value system and backed by a highly motivated staff, BDD is a breakout company with a fully customizable menu of business options to fit every need. To get to know BDD Marketing and Management better please go to www.BDDCorporation.com.

For more information on 877-FOR-INSURANCE, contact Kelly Downey of Shamin Abas Public Relations at [email protected] or 561.366.1226.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – September 28, 2010) –  iiBIG presents the Next Generation Pharma Sales & Marketing Summit, scheduled for November 16-17, 2010 at the Baltimore Marriott Inner Harbor at Camden Yards in Baltimore, MD. The pharmaceutical sales and marketing landscape has changed dramatically over the past few years with an expectation of global sales of pharmaceuticals to grow at a rate of 5%-8% annually over the next five years. At the center of this highly regulated industry emerges an increase of communications, digital marketing efforts, social media and sales force success strategies. Today’s pharmaceutical executives continue to create and implement influential campaigns with the goal of ultimately improving health outcomes by exploring new and dynamic selling techniques. At the same time, pharmaceutical sales representatives face increasing difficulty due to falling physician accessibility, stronger regulation in the industry, and changing operational models surrounding healthcare delivery.

This event will address the value of both sales and marketing operations within large, mid-size, and specialty pharmaceutical companies. It will feature keynote presentations from industry leaders, panel debates, relevant case studies, and high-level networking. This is an essential opportunity for any executive striving to make the most out of cutting-edge and alternative sales and marketing innovation best-practices.

The executive speaking faculty includes: A.T. Kearney; Acorda Therapeutics; Amarin Corporation; Astellas Pharma; AstraZeneca; Baxter; Biomet Microfixation; Bristol-Myers Squibb; comScore, Inc.; Covidien; Daiichi Sankyo, Inc.; Digitas Health; Epocrates; Genentech; Genzyme Genetics; GSW Worldwide; Harris Interactive; HighPoint Solutions; King Pharmaceuticals; Klick Pharma; Lundbeck Inc.; M2 Worldwide; MedImmune; NicOx; NuPathe; OSI Pharmaceuticals; Pacific Bridge Medical ; Pfizer; Physicians Interactive; PricewaterhouseCoopers ; Saint Joseph’s University; Sequella; Shire Pharmaceuticals; SymCare Personalized Health Solutions, Inc. (a Johnson & Johnson Company); Symphogen, Inc.; Teva Pharmaceuticals; UCB, Inc.; and WellDoc Communications, Inc.

For conference details: http://www.iibig.com/P1005

ABOUT iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. We provide learning and networking settings for some of the business community’s BIGgest thinkers – those who occupy the highest levels in their companies and organizations. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com.

FAIRFAX, VA–(Marketwire – September 28, 2010) –  FOAA Anesthesia Services, a leading provider of anesthesia services, today announced the unveiling of its enhanced web site at www.foaa.net. The web site is designed to enhance the user experience and communicate the organization’s mission and anesthesia service solutions to hospitals, ambulatory surgery centers (ASC) and medical offices. Combining a number of new navigation tools with an updated identity, the web site was built on a user-friendly platform with easy-to-use navigation tools.

“We want everyone to know about the world-class quality and customer service we provide in anesthesia services. We also want to ensure the FOAA web site reflects the vision of our organization and provides an overview of the services offered and the related activities in which we are involved,” explained Vincent J. Vilasi, president of FOAA Anesthesia Services. “The FOAA web site offers our partner hospitals, ASCs, medical offices, surgeons and their patients valuable information and links, answers to frequently asked questions and serves as a portal through which we can be contacted.”

“With a few clicks, anyone visiting the web site will be able to find information and solutions to anesthesia service delivery issues facing hospitals, ASCs, and medical offices,” Dr. Vilasi added.

About FOAA Anesthesia Services
For over twenty years, FOAA Anesthesia Services has been dedicated to providing the highest quality anesthesia services for patients, surgeons, physicians and healthcare facilities. FOAA cares for over 80,000 patients a year at multiple sites in Virginia including hospitals, ambulatory surgical centers, endoscopy centers and medical and dental office-based practices. FOAA offers a full range of anesthesia and pain management services and is dedicated to providing high quality care, outstanding customer service and a work environment of choice. For further information call (703) 293-9590 or visit www.foaa.net.

TUSTIN, CA–(Marketwire – September 28, 2010) –  Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into an exclusive 5-year full-service distribution agreement with Phu Gia Trading Co. Ltd. to expand the Company’s Onko-Sure™ IVD cancer test into the Vietnam, Laos, and Cambodia healthcare markets.

Phu Gia has committed to purchase a minimum of 2,425 Onko-Sure™ kits over the duration of the agreement.  Phu Gia Trading Co. Ltd. will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure in diagnostic centers and clinical labs throughout the designated territory. Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure IVD cancer test at relevant healthcare conferences and events; and ensuring all relevant product marketing materials are available in local languages. The Phu Gia customer service team will also be responsible for responding to customer inquiries and technical questions. Phu Gia will work directly with the Vietnam Ministry of Health and other government officials to secure approvals and regulatory clearances.   

“Our full-service distribution partnership with Radient allows us to work closely with top diagnostic centers and clinical labs in Vietnam, and reach healthcare professionals across the designated territories of Vietnam, Cambodia and Laos. Cancer continues to be one of our gravest healthcare challenges and Onko-Sure offers a valuable new tool for cancer detection and cancer treatment monitoring,” commented Jack Nguyen, President, Phu Gia. “We plan to commit extensive outreach resources to oncology thought leaders along with automating the Onko-Sure test at top labs — including the Ho Chi Minh Diagnostic Centre, to increase cancer testing across our region.”

“With a significant cancer challenge, Asia continues to show an increased demand for cancer diagnostic products like Onko-Sure,” commented Mr. Douglas MacLellan, Executive Chairman and CEO of RPC. “Phu Gia becomes our third distribution partner for Onko-Sure in the rapidly expanding Asia healthcare market, and we feel confident in our ability to gain strong market share throughout the region as we establish long-term agreements with well positioned partners like Phu Gia.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko?Sure is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring. 

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.radient-pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of our Onko Sure™ In Vitro Diagnostic cancer test. Our focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Radient Pharmaceutical’s current Onko-Sure™ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com. 

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

IRVING, TX–(Marketwire – September 28, 2010) – VHA Inc., the national health care network, is launching a satellite television series on health care reform and its impact on hospitals and health systems. The series, which will air on vhatv, will be hosted by VHA Senior Vice President of Corporate Affairs and General Counsel Michael Regier, and will feature government officials, health policy experts and VHA executives.

“The Affordable Care Act is bringing sweeping changes for hospitals and health systems, and the only thing more complex than the Act is the implementation process,” said Regier. “This series is just one way that VHA is working with its members to make sense of these significant changes and to prepare for the new demands they will face.”

The broadcast series, which starts Sept 28 and occurs every other month through September 2011, will cover topics such as the new requirements for tax-exempt hospitals, Accountable Care Organizations, health care issues facing the upcoming 112^th Congress and The Center for Medicare and Medicaid Innovation.

“Reform will require hospitals to dramatically cut their cost of care delivery over the next 10 years, and VHA has a proven track record of helping hospitals save money by reducing their supply spend,” says Regier. “However, we think there’s an equal opportunity to improve the quality of clinical care and to redesign its delivery, and we’re working with members in those areas, too.”

Each Focus on Reform broadcast in the new vhatv series will be made available for public viewing on VHA’s website. To view the broadcast via webcast, please visit the VHA website to register.

About VHA
VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. In 2009, VHA delivered record savings and value of $1.47 billion to members. Formed in 1977, through its 16 regional offices, VHA serves1,400 hospitals and more than 30,000 non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

WAKEFIELD, RI–(Marketwire – September 28, 2010) – ChartWise Medical Systems, Inc. has signed a strategic agreement with 3M Health Information Systems to provide 3M Grouper Plus Software integrated with ChartWise:CDI. ChartWise:CDI is a new software program that assists hospitals in improving clinical documentation in order to help maximize DRG-related reimbursements, reduce Medicare audit risk, and provide oversight and compliance. Available with the Enterprise Edition of ChartWise:CDI, 3M Grouper Plus Software facilitates accurate and efficient grouping, editing, and calculation of expected reimbursement, and supports complete and accurate documentation of the patient’s visit. Additionally, the integrated software will allow administrators to run reports to evaluate the financial impact of their hospital documentation improvement programs.

“One of the advantages that ChartWise:CDI provides customers is grouper software integrated directly with our solution. We prompt users to consider overlooked diagnoses that can be combined into a DRG code, possibly increasing allowable billing and reimbursement,” said Dr. Jonathan Elion, creator of ChartWise:CDI. “Our agreement with 3M will give our customers a proven grouping solution that clearly adds value to our product.”

About ChartWise
ChartWise Medical Systems, Inc. based in Wakefield, RI, is a medical software firm and the developers of ChartWise:CDI and ChartWise:CDI Personal Edition, a hosted solution for clinical documentation improvement. ChartWise:CDI’s clinical intelligence expertise assists physicians and clinical documentation specialists with increased efficiencies and completeness of documentation, queries and work flow. Developed by renowned physician, Jon Elion, M.D., ChartWise:CDI is the only documentation software that translates clinical language used by physicians into accurate diagnostic language required for Medicare documentation. For more information, visit www.chartwisemed.com.

About 3M Health Information Systems
3M Health Information Systems delivers comprehensive software and consulting services to help organizations worldwide improve documentation, quality and financial performance across the healthcare continuum. 3M offers integrated solutions for transcription, speech recognition, clinical documentation improvement, documentation management, computer-assisted coding, quality and revenue cycle management, effectively meeting the industry’s changing needs. With more than 25 years of healthcare experience and expertise, 3M works as a trusted and stable business partner to provide reliable implementation, training and support services. http://www.3Mhis.com